Advances in antibody-drug conjugates in the treatment of urothelial carcinoma
10.12483/j.issn.1009-8291.2026.01.016
- VernacularTitle:抗体偶联药物用于尿路上皮癌治疗的研究进展
- Author:
Tianxiang ZHOU
1
;
Haojie LIU
1
;
Sihai SHAO
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Huzhou University, Huzhou 313000, China
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugate;
urothelial carcinoma;
nectin cell adhesion molecule 4;
trophoblast cell surface antigen 2;
human epidermal growth factor receptor 2
- From:
Journal of Modern Urology
2026;31(1):91-95
- CountryChina
- Language:Chinese
-
Abstract:
The conventional treatment strategies offer limited efficacy in advanced or recurrent cases of urothelial carcinoma.Antibody-drug conjugates(ADCs), as a novel type of targeted therapy, deliver cytotoxic agents directly to tumor cells with both high potency and specificity, making them an important tool in precision oncology.This review systematically summarizes the structural components of ADCs and their antitumor mechanisms, including targeted antigen internalization and bystander effect.It also highlights key clinical research findings of representative ADCs, such as nectin cell adhesion molecule 4, trophoblast cell surface antigen 2, and human epidermal growth factor receptor 2.Furthermore, the article addresses the current challenges in the application of ADCs, such as drug resistance, toxicity management, and high cost, while exploring the development of next-generation ADCs and their potential in combination with immunotherapy.Based on current evidence, this review aims to offer valuable insights to support the clinical application and future research of ADCs in the treatment of urothelial carcinoma.
